Oxb-102 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 6 | パーキンソン病 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03720418 (ClinicalTrials.gov) | October 17, 2018 | 16/10/2018 | Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease | A Phase I/II Safety and Dose Evaluation Study of OXB-102 in Patients With Bilateral Idiopathic Parkinson's Disease | Parkinson Disease | Drug: OXB-102;Other: Imitation Surgical Procedure (ISP) | Axovant Sciences Ltd. | Oxford BioMedica | Recruiting | 30 Years | 70 Years | All | 30 | Phase 1;Phase 2 | France;United Kingdom |